ian duration of follow-up after CCRT was 6.5 months (range, 1.1-17.6, Table [4](#T4){ref-type="table"}). The one-year survival rate was 36.8%, and median survival time was 6.5 months (range 1.1-21.0). The median survival time in group I (patients with locally advanced disease without metastases) was 9.25 months (range, 2-18.4, Table [5](#T5){ref-type="table"}). In comparison with patients who had locally advanced and unresectable disease without metastases or a previous chemotherapy history, the others (those who had metastases at the time of CCRT, and a case with local relapse after previous curative surgery as well as those with a history of previous chemotherapy) showed poor survival (*p*= 0.063); 4.4 months (range, 1.1-21) versus 12.55 months (range, 6.5-18.4). Of the patients in group I, those who had no history of previous chemotherapy survived better than those with a history of previous chemotherapy (*p*= 0.0009); 12.55 months (range, 6.5-18.4) versus 3.9 months (range, 2-5.8).

###### 

Clinical outcomes in the nineteen patients treated with tomotherapy and concurrent capecitabine

  Patient   Overall In-field tumor response   Duration of tumor response (months)   Treatment-related toxicity     Duration of follow-up after tomotherapy (months)   Out-field progression state   Cause of death other than cancer progression   Duration of survival after tomotherapy (months)
  --------- --------------------------------- ------------------------------------- ------------------------------ -------------------------------------------------- ----------------------------- ---------------------------------------------- -------------------------------------------------
  1         Stable disease                    5.9                                   fatigue (grade 2)              7.3                                                Progressed                                                                   7.3
  2         Partial response                                                        hand foot syndrome (grade